BARR PHARMACEUTICALS INC Form 8-K April 27, 2007

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 23, 2007 BARR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 1-9860 42-1612474
(State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677
(Address of principal executive offices) (Zip code)

(201) 930-3300

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

<u>Item 1.01 Entry into a Material Definitive Agreement SIGNATURES</u>

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement

On April 23, 2007, Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (the Company), entered into an agreement with Urdang/IPA-Montvale, LLC to lease a new U.S. headquarters facility in Montvale, New Jersey.

The new 142,500 square foot facility is located less than two miles away from, and is nearly 60% larger than, the Company s existing headquarters facility in Woodcliff Lake, New Jersey. The new headquarters will enable the Company to consolidate personnel currently working in various locations, keep its headquarters located in the same area and meet the needs of staff expansion that have resulted from both internal growth and its 2006 acquisition of PLIVA d.d. The Company intends to sublease its existing headquarters facility in Woodcliff Lake, which it first occupied in 2003.

The term of the new lease is 10.5 years, and is expected to commence in August 2007, when the Company plans to begin to take possession of the leased premises. The base rent payable during the first five years of the rental term will be \$320,625 per month, increasing to \$356,250 per month thereafter through expiration.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BARR PHARMACEUTICALS, INC.

Date: April 26, 2007 /s/ William T. McKee William T. McKee

Vice President, Chief Financial Officer,

and Treasurer